Interviews

Sagar Lonial, MD, lead investigator of the phase 3 EXCALIBER trial, dissects iberdomide data he presented at IMS 2026 and where mezigdomide fits in.

Tennessee Oncology’s Johnetta Blakely, MD, MS, explains why physicians must review high-stakes AI-assisted orders and how patients view AI in oncology.

OneOncology's Edward "Ted" Arrowsmith, MD, MPH, explains why cost stays out of its pathway process and how point-of-care ordering puts pathways to work.

Tennessee Oncology's Wade Iams, MD, MSCI, discusses insured patients' out-of-pocket costs, platinum shortages, and access to CAR T and BiTE therapies.

Zidesamtinib offers better tolerability in ROS1-positive NSCLC, but adverse effects still need monitoring, and optimal sequencing remains unclear.

Nicolas Ferreyros, of COA, warns IRA drug price negotiation threatens community oncology payments and urges Part B, 340B, and insurer reforms.

Michael Mina, MD, PhD, of Invivyd explains how a few amino acid changes let VYD2311 move from IV to a single IM shot that could expand access.

Fathi, of Mass General Brigham Cancer Institute, says PARADIGM trial data support azacitidine-venetoclax for induction-eligible patients.

Joanna Parga-Belinkie, MD, explains how framing VKDB as a stroke and documenting refusals helps her counsel parents on vitamin K.

Alyssa Schatz, DrPH, MSW, of NCCN, explains how insurance shifts and drug shortages threaten access to cancer care.

Moffitt’s Andrew Kuykenda, MD, lead VERIFY trial investigator, says rusfertide offers durable response and manageable safety.

OneOncology's Larry Bilbrey discusses why unstructured data limits artificial intelligence and how practices can weigh AI purchases by their payoff.

AI tools are streamlining retina practice, but adoption depends on fitting them into real-world workflows.

Cataract surgery improved vision across all AMD stages, but patients with advanced dry AMD lost their gains by about 30 months.

New 12-month phase 1/2 data show the BIM-IOL System lowered IOP and kept most patients drop-free after cataract surgery.

In the pivotal BRUNELLO trial, both doses of remigromig, a Wnt pathway agonist, were noninferior to ranibizumab for diabetic macular edema at 1 year.

Access to emergency eye care remains a public health challenge, with gaps that affect patients and communities across the country.

Cost, staffing, unbiased training data, and strong referral partnerships will decide whether AI eye screening reaches patients at highest risk of vision loss.

Michael Mina, MD, PhD, explains LIBERTY trial findings on VYD2311 tolerability alone and given with an mRNA COVID-19 vaccine.

The director of the National Eye Institute discusses recent advances, AI, and evolving standards of care in ophthalmology.

Duration of benefit "has to be part of the discussion," emphasizes Rogers of The James/The Ohio State Comprehensive Cancer Center.

COA's Nicolas Ferreyros discusses real-world survival data for community oncology, health system consolidation, and barriers to CAR T-cell access.

Cathy Eng, MD, discusses a BREAKWATER post hoc analysis showing poorer survival in early-onset BRAF V600E colorectal cancer.

Cleveland Clinic's Beth Faiman, PhD, MSN, discusses AP-led clinics, managing talquetamab taste changes, and infection prophylaxis with bispecifics.

Joanna Parga-Belinkie, MD, of CHOP explains how she tailors counseling to address vitamin K shot misinformation and VKDB risks.

Stutsky explains why shifting therapy perceptions had more pharmacist touchpoints and longer time on therapy among patients with ATTR-CM.

Transplant is no longer the default for young, fit patients with a good donor if they achieve MRD-negative status, says Emily K. Curran, MD

Mitchell Blewett, PharmD, MS, of Cleveland Clinic, explains why formulary approval is only the midpoint before a new oncology drug reaches patients.